Communicating With Your Oncologist About Cannabis Use

Many Australians with cancer consider medicinal cannabis for pain, nausea, poor sleep, appetite changes, anxiety or treatment-related discomfort. Some also investigate cannabidiol (CBD), tetrahydrocannabinol (THC), cannabis oils and complementary approaches after hearing personal accounts online. These conversations can feel sensitive, particularly when a person worries that their oncology team may dismiss the idea or interpret it as refusing conventional treatment.

A productive discussion is based on openness, accurate product information and realistic goals. Cannabis is not a proven replacement for chemotherapy, radiotherapy, surgery, immunotherapy or hormone treatment. However, a clinician may help assess whether a regulated medicinal cannabis product could fit safely alongside a cancer care plan, or explain why it may be unsuitable.

Choose The Right Time For The Conversation

Raise the subject during a planned appointment rather than waiting until severe pain, vomiting or distress makes decision-making harder. Tell the receptionist or nurse that you want to discuss medicinal cannabis so the appointment has enough time. A telehealth consultation can also be useful for people living outside Sydney, Melbourne, Brisbane, Perth or other major centres, where specialist access may be limited.

Begin with your treatment goal. For example, explain that you are seeking help with chemotherapy-induced nausea, nerve pain, sleep disruption or appetite loss. Describe how often the symptom occurs, how intense it is, what makes it worse and whether prescribed medicines have helped. This gives the oncologist a clinical problem to assess instead of a broad request for “cannabis treatment.”

Use straightforward language and disclose any products already taken, including oils purchased online, dried flower, gummies, vaping products or preparations supplied by friends. Even occasional use matters because THC and CBD can affect alertness, blood pressure, liver enzymes and the action of other medicines.

Prepare A Complete Medication Record

Take a current list of every prescription, over-the-counter medicine, vitamin, herbal supplement and recreational substance. Include dose, timing and the reason for use. Cancer patients may take antiemetics, opioids, anticoagulants, corticosteroids, antidepressants, sleeping tablets or targeted therapies, and combinations can create clinically important risks.

Bring the product packaging or a photograph of the label if you have already used cannabis oil. Record the stated CBD and THC concentration, batch details, route of administration and supplier. A bottle labelled simply “hemp oil” does not provide enough information to establish its cannabinoid content or purity. Products can vary substantially in strength, and an online description is not a substitute for independent quality assurance.

Ask whether the oncology pharmacist, hospital pharmacist or GP should review the product. CBD may influence enzymes involved in drug metabolism, potentially changing exposure to some anticancer medicines. Sedation can become stronger when cannabis is combined with opioids, benzodiazepines, alcohol or other medicines that slow the nervous system. A clinician may recommend monitoring, a different product or avoiding cannabis altogether.

Understand Australian Access Rules

In Australia, medicinal cannabis is generally prescription-only. Access commonly occurs through a doctor authorised to prescribe a particular product or through the Therapeutic Goods Administration’s Special Access Scheme or Authorised Prescriber pathways. The process may involve a GP, oncologist, pain specialist or another qualified practitioner, and requirements can vary according to the product and patient circumstances.

A prescription does not mean every pharmacy stocks the requested formulation. Supply, cost and availability may differ between metropolitan areas and regional communities. Patients in rural New South Wales, Queensland or Western Australia may need to arrange dispensing through a compounding or specialist pharmacy, while delivery arrangements must comply with Australian rules. Ask who will prescribe, who will dispense, how follow-up will occur and what happens if the product is unavailable.

Medicinal cannabis is different from non-prescription CBD products sold through informal websites or overseas suppliers. The TGA has warned that many products promoted as CBD may be unapproved, inaccurately labelled or legally restricted. The legal status of possession, driving and workplace use also matters. Even with a prescription, THC can affect driving ability, and roadside drug-testing laws may create serious consequences. Obtain current advice from the prescriber and relevant state or territory authorities before driving.

Separate Symptom Relief From Cancer Claims

A useful consultation distinguishes supportive care from claims that cannabis can shrink tumours or cure cancer. Evidence for cannabis-based medicines is strongest or more established in selected symptom-control settings, while evidence for treating cancer itself remains limited and condition-specific. Cannabis should not be used to delay biopsy, surgery, systemic therapy, radiotherapy or urgent assessment of new symptoms.

Ask what outcome would count as success. It might be fewer vomiting episodes, improved sleep, reduced neuropathic pain or less reliance on rescue medication. Agree on a review date and a way to track the result. A simple diary can record pain scores, nausea, appetite, sleep quality, bowel changes, dizziness, confusion and the timing of every dose.

Some people explore cannabis alongside dietary changes. If a ketogenic dietary plan is being considered, review it with the oncology team and an accredited practising dietitian because weight loss, malnutrition and treatment tolerance are central concerns in cancer care; a ketogenic dietary plan should not be started without individual clinical guidance.

Discuss Formulations And Administration

Cannabis medicines may contain CBD, THC or a measured combination of cannabinoids. CBD is not intoxicating in the same way as THC, yet it can still cause sleepiness, diarrhoea, appetite changes or medicine interactions. THC may produce euphoria, anxiety, impaired coordination, rapid heartbeat or altered thinking. Older adults and people with a history of psychosis, severe anxiety, heart disease or falls may face additional risks.

The method of administration changes how quickly effects begin and how long they last. Oral oils and capsules may take time to work and can have delayed, prolonged effects. Inhaled products act more quickly but may pose respiratory concerns and can make dose estimation difficult. Rectal preparations are sometimes discussed in specialist settings, but they require careful advice about formulation, absorption, hygiene and interactions with local treatment.

Do not change from one route to another using the same volume or dose. A clinician may recommend starting with a low amount and adjusting gradually, but dosing must be individualised rather than copied from a social media post or another patient’s plan. Avoid combining cannabis with alcohol, driving, operating machinery or making important decisions until the effects are known.

Ask About Evidence, Interactions And Monitoring

Invite the oncologist to explain the evidence relevant to your cancer type, current therapy and specific symptom. A clinical review of cannabis oil for nerve pain may be more relevant to someone with chemotherapy-induced peripheral neuropathy than a general testimonial, but research findings still need to be interpreted alongside individual risks. Patient stories can describe experiences, yet they cannot establish effectiveness or safety for everyone; clinical evidence on neuropathic pain should be considered as part of a broader medical discussion.

Ask whether cannabis could affect blood counts, liver function, sedation, immune-based treatment or the absorption of oral medicines. Enquire about warning signs that require urgent attention, such as severe confusion, fainting, chest pain, persistent vomiting, hallucinations, allergic symptoms or extreme drowsiness. People receiving active treatment should know whether they need blood tests or a medication review after starting a cannabinoid product.

If the oncologist is not comfortable prescribing, ask for a referral to a doctor with medicinal cannabis experience, a palliative care service or a clinical pharmacist. Palliative care is available at any stage of serious illness and focuses on pain, symptoms, emotional wellbeing and family support; it does not mean that anticancer treatment has stopped.

Protect Privacy And Include Your Support Network

Cannabis use can carry stigma, so choose a professional service with clear privacy practices and proper clinical governance. Be cautious about sending medical records, identity documents or payment details to websites that make guaranteed cure claims, pressure patients to purchase quickly or fail to identify a registered prescriber. A legitimate consultation should include a medical history, current medicines, treatment details, contraindication screening and follow-up.

Some patients use overseas services while seeking information about alternative cancer protocols. CBD International describes cannabis and CBD products, patient consultations and treatment support, but online information should be discussed with the Australian clinician coordinating your care. Imported or privately supplied products may not meet Australian regulatory requirements, and the treating team needs to know exactly what has been taken.

Ask a trusted family member to attend the appointment or take notes, particularly if fatigue, pain or anxiety makes it difficult to remember details. Agree on who will monitor changes at home and how concerns will be reported. Families should understand that a patient’s decision about medicinal cannabis remains personal, while safe use depends on honest communication with the healthcare team.

Create A Shared Care Plan

Before leaving the appointment, clarify the product name, cannabinoid content, starting instructions, maximum amount, timing and review date. Confirm whether the medicine should be taken with food and what to do after a missed dose. Establish who will manage repeat prescriptions and whether the oncologist, GP, pain specialist or palliative care team will coordinate follow-up.

A written plan should identify which symptom is being treated, how improvement will be measured and when the medicine will be stopped. It should also list other medicines that must be avoided, including alcohol or sedatives if relevant. Do not stop an anticancer medicine, opioid or anti-nausea treatment abruptly without professional advice.

Review the plan if cancer treatment changes, a new medicine is added, liver or kidney function worsens, pregnancy becomes possible or falls and confusion develop. Cannabis use should remain one documented part of comprehensive cancer care rather than a private experiment outside the medical record.

Bring your product information, symptom diary and complete medication list to your next appointment. Ask an Australian-registered healthcare professional to assess suitability, explain legal access and monitor the results, while keeping prescribed cancer treatment and urgent medical care on schedule.